TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01845025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match formoterol one inhalation twice daily via dry powder inhaler
Study: NCT04102501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
Study: NCT00059475
Drug: Glycoprotein 100 (GP100): 209-217 (210M)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01837082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03127020
Drug: PQR309
Approvals — FDA: no, EMA: no, PMDA: no
Description: taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
Study: NCT00059475
Drug: Melanoma antigen recognized by T-cells (MART)-1: 27-35
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00059475
Drug: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00059475
Drug: melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02338362
Drug: Saline placebo inhaler
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline metered dose inhaler
Study: NCT02426632
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
Study: NCT02426632
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
Study: NCT02426632
Drug: Formulation D
Normalized name: Complete Formulation D3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
Study: NCT02426632
Drug: Formulation M1
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study: NCT02426632
Drug: Formulation M2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study: NCT02426632
Drug: Formulation M3
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study: NCT02426632
Drug: Formulation N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study: NCT02426632
Drug: Formulation N2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study: NCT02426632
Drug: Formulation N3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study: NCT00524095
Drug: azithromycin and fluticasone
Normalized name: salmeterol and fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
Study: NCT00524095
Drug: fluticasone and azithromycin
Normalized name: salmeterol and fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
Study: NCT04281537
Drug: Enzyme Replacement Therapy (ERT)
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERT infusion every other week
Study: NCT00811226
Drug: olmesartan medoxomile alone or combined with hydrochlorothiazide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
Study: NCT01121406
Drug: Pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive PLD in a 4 week schedule
Study: NCT01940718
Drug: Transdermal Androgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (\~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
Study: NCT03827876
Drug: Enstilar 0.005%-0.064% Topical Foam
Normalized name: Enstilar 0.005%-0.064% Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
Study: NCT01917825
Drug: MDT-15
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02610283
Drug: QPI-1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection
Study: NCT01458769
Drug: Reyataz®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
Study: NCT00659438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, once daily
Study: NCT01633060
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 100 mg once daily
Study: NCT01633060
Drug: BKM120 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 matching placebo, once daily
Study: NCT04332549
Drug: PICS (Reconstitution Method 1 or 2)
Normalized name: Inova 8-2 Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
Study: NCT03694522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion over approximately 30 minutes
Study: NCT03694522
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours
Study: NCT01533155
Drug: Nektar 118
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 25 mg tablet
Study: NCT02085655
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT01164501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical to BI 10773 low dose
Study: NCT01164501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical to BI 10773 high dose
Study: NCT02515669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
Study: NCT00957372
Drug: placebo (Part I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily placebo comparator
Study: NCT01282814
Drug: Effexor® XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Extended-Release Capsule
Study: NCT01367743
Drug: epinephrine perfusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
Study: NCT02490540
Drug: Sufentanil SPI analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
Study: NCT02490540
Drug: Sufentanil ANI analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
Study: NCT02490540
Drug: Sufentanil anesthesiologist analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
Study: NCT02904564
Drug: MMP with Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMP with saline infusion using tattoo device
Study: NCT02100553
Drug: CE/BZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.45mg/BZA 20mg tablets, single dose on Day 5
Study: NCT02100553
Drug: CE/BZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.45mg/BZA 20mg tablets, single dose
Study: NCT02021422
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fluorouracil 2400 mg/m2 48 hours
Study: NCT01134510
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS (comparable volume as intervention) twice weekly x 4wks
Study: NCT00775372
Drug: Clarithromycin 250mg/5mL
Normalized name: CLARITHROMYCIN 250MG/5ML SUSP
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00377299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching active medication in all other physical aspects
Study: NCT03984526
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
Study: NCT04163783
Drug: [14C]-BGB-3111
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg capsule containing \~200 μCi of \[14C\]-BGB-3111,
Study: NCT03667651
Drug: EpiCeram
Normalized name: EPICERAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
Study: NCT01332435
Drug: 5ARI + AB
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
Study: NCT02660580
Drug: MSB11022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.
Study: NCT00896519
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00896519
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03563248
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~* Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle
Study: NCT04745442
Drug: Best available treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will be treated with the best available treatment for COVID-19.
Study: NCT03348683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
Study: NCT03335124
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.
Study: NCT03335124
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous thiamine will be applied as per instructions described in arm/group descriptions.
Study: NCT03448835
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 850 mg /m2 4 cycles
Study: NCT01483846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
Study: NCT01717846
Drug: Group 1 or Orencia treated group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
Study: NCT03937986
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of placebo will be determined.
Study: NCT02641899
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen 1000 mg on Day 1 and Day 27
Study: NCT00345371
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01223911
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
Study: NCT02857465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
Study: NCT02857465
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
Study: NCT00435539
Drug: Sham Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal sham injection
Study: NCT02202603
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: NCT02870673
Drug: SHINCORT
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamcinolone Acetonide (10mg/ml) 0.5 ml
Study: NCT00159484
Drug: EPO906, celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
Study: NCT02242279
Drug: BEA 2180 BR
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02085577
Drug: Usual daily opioids
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients usual daily opioid consumption are administered during the study period
Study: NCT02085577
Drug: Sufentanil 5 microgram/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
Study: NCT03103399
Drug: Comtan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
Study: NCT03103399
Drug: Levodopa/DDCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients.
Study: NCT03103399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
Study: NCT03388970
Drug: Vitamin K 1
Normalized name: vitamin K 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Research group use Vitamin K1
Study: NCT03388970
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group use normal saline
Study: NCT00252863
Drug: Symbicort, used twice daily (b.i.d) and as needed (prn)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00252863
Drug: Theophylline 200 mg
Normalized name: theophylline 200 MG
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00252863
Drug: Theophylline 300 mg
Normalized name: theophylline 300 MG
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01383941
Drug: Guidelines-based asthma and rhinitis/rhinosinusitis therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
Study: NCT03952130
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03933501
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
Study: NCT02396147
Drug: TAK-385 T2 Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 T2 Formulation tablets
Study: NCT02396147
Drug: TAK-385 T4 Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 T4 Formulation B tablets
Study: NCT02832271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04889677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01583647
Drug: MK-0524A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
Study: NCT01583647
Drug: MK-0524A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
Study: NCT02325882
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional fentanyl-based epidural PCA
Study: NCT02325882
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional fentanyl based intravenous PCA
Study: NCT02652819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01718314
Drug: Placebo (for Misoprostol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
Study: NCT01718314
Drug: Placebo (for Lidocaine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
Study: NCT00719810
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg then 50 mg intravenous tigecycline every 12 hours
Study: NCT03067597
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The DVI contains 10 mg dinoprostone
Study: NCT03976401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT03088605
Drug: TOP1630 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ocular drug administration
Study: NCT03088605
Drug: Placebo to TOP1630 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ocular drug administration
Study: NCT00262106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00149214
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
Study: NCT00149214
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
Study: NCT02282761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01382069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with capsules that look like the DMAU capsules but with no active ingredients
Study: NCT00184990
Drug: endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01673061
Drug: Vapocoolant
Approvals — FDA: no, EMA: no, PMDA: no
Description: See associated Arm Description